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One important mechanism by which cancer cells parasitize their host is by escaping apoptosis. Thus, selectively facilitating
apoptosis is a therapeutic mechanism by which oncotherapy may prove highly advantageous. One major apoptotic pathway is
mediated by Fas ligand (FasL). The death-inducing signaling Ccmplex (DISC) and subsequent death-domain aggregations are
created when FasL is bound by its receptor thereby enabling programmed cell death. Conceptually, if a better understanding of
the Fas pathway can be garnered, an oncoselective prodeath therapeutic approach can be tailored. Herein, we propose that EGF
and CTGF play essential roles in the regulation of the Fas apoptotic pathway in sarcomas. Tumor and in vitro data suggest viable
cells counter the prodeath signal induced by FasL by activating EGF, which in turn induces prosurvival CTGF. The prosurvival
attributes of CTGF ultimately predominate over the death-inducing FasL. Cells destined for elimination inhibit this prosurvival
response via a presently undefined pathway. This scenario represents a novel role for EGF and CTGF as regulators of the Fas
pathway in sarcomas.
1. Introduction
Sarcomas, as cancers of mesenchyme, are rare and often quite
deadly. Neoplastic processes arising in tissues of mesenchy-
mal origin occur less frequently than those of ectodermal or
endodermal origin, but behave in a very aggressive manner.
In the United States, sarcomas have an annual incidence of
over 10,000 cases per annum. Although relatively uncom-
mon, these tumors as a group can behave in a nefarious fash-
ion with currently reported mortality rates for certain sub-
types greater than 50% [1]. As sarcomas arise in all parts
of the body, especially the musculoskeletal system, the as-
sociated morbidity is substantially higher. Sarcomas inflict
a tremendous emotional, physical, and financial toll on
individuals and society alike. Furthermore, sarcomas affect
patients of all ages, with 15% arising in patients younger than
15 years and 40% in patients older than 55 years. Accordingly,
as the population ages, the incidence of these cancers will
likely increase [2].
Aphoristically, the norm for a patient afflicted with meta-
static sarcoma is death after an almost invective conflagration
of mutilating surgery, radiation, and cytotoxic chemother-
apy. Survival rates for stage IV sarcoma are 25% at best with
this current triumvirate of clinical care [3]. Biotargeting has
fueled limited optimism in the form of inhibitors of tyrosine
kinases, mammalian target of rapamycin (mTOR), insulin
growth factor receptor (IGFR), and histone deacetylase
(HDAC) as well as others that selectively block prosurvival
pathways [4]. Unfortunately, even with a more sophisticat-
ed inhibitory approach, many cancers circumvent a given
blocked pathway to maintain a survival advantage and thus
disadvantaging the patient. Facilitating apoptosis selectively
in the cancer cell is another mechanism by which oncother-
apy may prove highly advantageous. Unfortunately, detailed
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pursuit in understanding programmed cell death and the
factors that influence it, even in the normal cell, has been a
challenge.
Fas/AP0-1/CD95 (tumor necrosis factor receptor super-
family, member 6) is the best characterized of the 29 recep-
tors currently placed within the tumor necrosis factor (TNF)
receptor superfamily. Fas induces apoptotic cell death when
cross-linked with its membrane-bound ligand (FasL) [5], but
can also demonstrate prosurvival properties by way of its
interaction with signaling pathways that influence cell acti-
vation, proliferation, survival, and differentiation [6, 7]. Fas
is expressed on a wide variety of cell types, including T cells
and activated B cells, and plays a pivotal role in the regulation
of the immune system [8]. Overexpression of Fas contributes
to the pathogenesis of various malignancies, including lung
cancer [9], colorectal cancer [10], breast cancer [11], and
sarcomas [12, 13]. FasL is transcriptionally inactive in many
cell types [14], but expression can be induced in vivo by
DNA damage, or in vitro by serum deprivation [15]. Fas
interaction with its ligand precipitates formation of the
death-inducing signaling complex (DISC), which includes
the adaptor protein Fas-associated death domain protein
(FADD/MORT1), plus caspases 8 and 10 (CASP8/10) [14].
In type I cells, processed CASP8 directly activates down-
stream effector caspases (e.g., CASP3) leading to cell death,
while in type II cells, activation of effector caspases depends
on the CASP8-mediated cleavage of proapoptotic BID (BH3
interacting domain death agonist) and the subsequent
release of mitochondrial proapoptotic proteins [16]. Recent
studies have identified a second Fas-associated death domain
protein: the death-domain-associated protein (DAXX). This
120 kD multifunctional protein modulates Fas-induced cell
death via the signal-regulating kinase 1 (ASK1)-MEK-c-Jun-
N-terminal kinase (JNK)/p38-Bax pathway [17]. DAXX also
functions as a dominant negative inhibitor of transforming-
growth-factor-beta- (TGFβ-) induced apoptosis [18].
In addition to regulating target cell lysis in the immune
system, Fas signaling also contributes to the establishment
of immune privilege and to tumor survival; therefore, the
clinical and pharmacological potential of Fas and/or FasL
as targets for therapeutic intervention has received consid-
erable attention [19]. Although there are relatively nontoxic
modulators of the Fas death pathway that are of potential
clinical significance (i.e., interferon and nonsteroidal anti-
inflammatory drugs—INSAIDs), systemic administration of
rhFasL in humans was not considered feasible due to the Fas-
mediated apoptosis of hepatocytes. Recent advancements in
the development of FasL therapy, however, may enhance FasL
efficacy. Compared to its membrane-bound counterpart,
soluble FasL (sFasL) has a reduced capacity to activate Fas,
even though all of the sequence information required for
receptor activation is latently retained in the soluble ligand
[20]. However, when bound to an appropriate antibody and
administered as an antibody/ligand fusion protein, sFasL
remains relatively inactive while enroute to the target, but
once bound to the cancer cell, sFasL is converted into a fully
active membrane ligand-like molecule [21]. Furthermore,
combining the application of LCL 204, an inhibitor of the
ceramide-metabolizing enzyme acid ceramidase, with FasL
gene therapy sensitized head and neck squamous cell cancer
cell lines to Fas-induced apoptosis both in vitro and in a
xenograft model in vivo [22]. These new findings potentially
open the door for renewed interest in employing FasL/Fas
therapy for cancers.
Some TNF ligands reportedly bind to more than one
member of the TNF superfamily of receptors [23], and
crosstalk occurs at the level of intracellular signal transducers
[24]. For example, FasL-induced cell death in tumor cells
of epithelial origin is inhibited following activation of the
epidermal growth factor receptor—EGFR/ErbB1 [25]. EGFR
activation of the Akt pathway is required and sufficient
for the anti-apoptotic function. EGF is a 6 kDa membrane
protein that binds and activates its 170 kDa cell surface
tyrosine kinase receptor. Extracellular ligand binding to the
EGFR triggers a series of intracellular signaling cascades
which collectively influence cell proliferation and survival,
differentiation, and cell migration [26, 27]. Deregulation of
signaling as a result of the aberrant expression of the EGFR
has been implicated in oncogenesis [28]. The primary signal-
ing pathways activated by EGF through the EGFR consist of
(1) the extracellular signal-regulated kinase (ERK) mitogen-
activated protein kinase pathway (MEK-ERK MAPK cas-
cade), (2) the phosphatidylinositol-3 kinase PI3 K/Akt path-
way, and (3) the signal transducer and activator of transcrip-
tion (STAT) pathway [29–32]. Although present in normal
cells, EGFR overexpression in tumor cells has been associated
with a poor prognosis and decreased survival and EGFR
activation is also involved in resistance to chemotherapy and
radiation treatment [33]. EGF also reportedly protects rat
prostatic epithelial cells from TGFβ1-induced cell death [34].
TGFβ1 (transforming growth factor beta 1), like EGF, can
modulate the FasL/Fas apoptotic pathway. TGFβ1 inhibits
Fas-induced cell death in pre-B-cells by blocking the PI3K
pathway [35]. TGFβ1 can also induce apoptosis through the
FasL-independent activation of the Fas death pathway in
human gastric SNU-620 carcinoma cells [36].
In view of the above, we suggest a relationship exists
between growth factor activity and modulation of the Fas
apoptotic pathway in mesenchymal tumors. In 1999, Gibson
et al. [25] reported that EGF protected epithelial cells from
Fas-induced apoptosis. Studies published by this laboratory
[37, 38], as well as our ongoing research, suggest a similar
inhibitory effect by EGF, but in mesenchymal cells. Sarcoma
transcriptional patterns imply the following scenario. Viable
cells within an untreated primary sarcoma are exposed to
FasL. To counter the prodeath signal induced by FasL, and
thus, tomaintain viability, the cells respond by inducing EGF,
which in turn activates (directly or indirectly) prosurvival
connective tissue growth factor (CTGF). The prosurvival
attributes of CTGF ultimately predominate over the death-
inducing FasL. Cells destined for apoptotic elimination in-
hibit this prosurvival response. We now propose three
genes—FasL, TGFβ1, and CTGF—are intimately involved in
the regulation of the Fas death pathway, and their coordi-
nation and respective contributions are modulated by EGF
in tumors of mesenchymal origin. Our tumor and in vitro
data strongly support a role for growth factor modulation of
Fas-induced cell death, possibly through EGFR activation of
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the MAPK signal transduction pathway. This scenario repre-
sents a novel role for EGF as a regulator of Fas-induced cell
death in mesenchymal neoplasms.
2. Materials and Methods
2.1. Sarcomas. Eighty-two primary sarcomas were acquired
from three institutions and processed according to IRB-
approved and HIPAA-compliant protocols. The 82 sarcomas
represented the 57 tumors used in our original evaluation
of the Fas death pathway [38], plus an additional 25 sarco-
mas included specifically for this analysis. Total RNA was
extracted and purified from the homogenized tissues using
RNeasy kits supplied by Qiagen (Germantown,Md, USA), or
by TRIzol according to the manufacturer’s recommendations
(Invitrogen, Carlsbad, Calif, USA). RNA quality was evalu-
ated using an Agilent Bioanalyzer (Santa Clara, Calif, USA).
Sarcoma histotypes (number of tumors/histotype) consisted
of chondrosarcoma (5), Ewing’s sarcoma (EFT-8), fibrosar-
coma (1), hemangiopericytoma (2), leiomyosarcoma (7),
liposarcoma (3), malignant fibrous histiocytoma (MFH-5),
malignant peripheral nerve sheath tumor (MPNST-9), myx-
ofibrosarcoma (3), osteosarcoma (7), rhabdomyosarcoma
(4), synovial sarcoma (9), and “unclassified” sarcoma (19).
2.2. Cell Culture. SW1353 chondrosarcoma cell cultures
(ATCC: HTB-94) in Leibovitz’s L-15 medium (Invitrogen)
containing 10% fetal bovine serum (FBS; Hyclone, Logan,
Utah, USA) were maintained in mid-log phase within a
37◦C humidified incubator containing 5% CO2. Culture
medium containing FBS is referred to hereafter as “complete
medium.” For experiments, a predetermined number of log-
phase SW1353 cells were inoculated in complete medium
into 25 cm2 tissue culture flasks one day prior to treatment.
Cell cultures were subsequently washed, serum-starved
(serum-free; SF) for 24 h, and then stimulated with 5 or
25 ng/mL recombinant human EGF (rhEGF; E9644; Sigma)
in SF medium at 37◦C for an additional 1 h or 24 h. Control
flasks received SF L-15 medium only. Following treatment,
cultures were washed and SF medium was added to each
flask. Cultures were incubated at 37◦C for an additional
24 h prior to processing for real-time RT-PCR. Total RNA
was extracted from cells using RNeasy kits (Qiagen). Com-
plementary in vitro experiments were analyzed for EGF-
induced gene expression when the cultures were maintained
and treated in complete L-15 medium. A minimum of three
separate experiments with three flasks per treatment dose
were conducted for both SF and completemedium protocols.
To determine the effect of receptor inhibitors on gene expres-
sion, SW1353 cultures were pretreated for 24 h with the
EGF receptor (EGFR) inhibitor AG1478 (tyrphostin; T4182;
Sigma), alone at 200 nM, or in combination with 200 nM
TGFβ receptor inhibitor SB431542 (Tocris Biosciences,
Ellisville, Mo, USA). Following the initial 24 h inhibitor
treatment, cultures were stimulated for an additional 24 h
with rhEGF coupled with the receptor inhibitor(s) prior to
being assayed for gene expression.
2.3. Real-Time RT-PCR Assays for Gene Expression. Tumor
and SW1353 cell mRNA content was quantified by real-time
RT-PCR using TaqMan Gene Expression Assays and the ABI
PRISM 7900 HT Sequence Detection System with related
software (Applied Biosystems, Foster City, Calif, USA). Glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) served as
the reference standard. Individual samples were screened
for the Fas-related genes EGF, TGFβ1, FasL, Fas, CTGF,
FADD, DAXX, SMAD3 (Mothers against decapentaplegic
homolog 3), SMAD7, CASP8, CASP10, and CFLAR (CASP8
and FADD-like apoptosis regulator). Real time RT-PCR cycle
scores were normalized by subtracting the sample GAPDH
cycle number from each gene cycle number.
2.4. Enzyme-Linked Immunosorbent Assay (ELISA) and Dot
Blotting. We quantified by ELISA protein concentrations
(pg/mL) of EGF, FasL (R&D Systems, Minneapolis, Minn,
USA), and TGFβ1 (YES Biotech Laboratories, Ltd, Missis-
sauga, ON, Canada) in 21 of the 82 sarcomas used in this
study. The 21 tumors represented the only sarcomas in the
82-tumor cohort whose soluble proteins were available for
use. We used a standard dot blot assay to document the
presence or lack of CTGF protein in the 21 sarcoma sam-
ples since commercial ELISA kits for CTGF are currently
unavailable. Tumor-soluble proteins were isolated from the
21 sarcoma samples using TRIzol and then quantified by
spectrophotometry using the BCA protein assay kit provided
by Thermo Scientific (Rockford, Il, USA). A colorimetric,
cell-based ELISA kit (RayBio Cell-Based EGFR (activated)
ELISA kit; RayBiotech, Inc., Ga, USA) was used to verify
EGFR activation following rhEGF stimulation of the SW1353
chondrosarcoma cell line.
2.5. Statistical Analysis. Statistical analyses were performed
using the Microsoft Office Excel 2003 statistical analysis
tool option as described previously [37, 38]. Briefly, the
GAPDH-normalized RT-PCR scores were tested for ran-
domness and normality (http://home.ubalt.edu/tsbarsh/stat-
data/Javastat.htm) prior to the parametric analysis. The
ABI PRISM 7900 HT sequence detection system reports an
mRNA concentration as “the cycle when amplification of the
target is first detected; the higher the starting copy number of
the nucleic acid target is, the sooner a significant increase in
fluorescence (i.e., the smaller the cycle number) is observed.”
Cycle values for our tumor and cell culture samples ranged
from 16 to 39. In order to accommodate the analysis, we
arbitrarily assigned a cycle value of 40 to individual samples
lacking detectable levels of mRNA. Forty represented one
cycle greater than the highest cycle value produced by the
lowest detectable level of mRNA (i.e., cycle 39). In view
of the fact that we lacked a reference plasmid of known
size, with known copy number, which would have been
used to define constituent copy numbers of transcripts, our
results are reported herein as cycle numbers, rather than as
absolute copy number. Ten Fas-related genes were assayed
for mRNA content in SW1353 cell cultures. FasL was not
detected in any of the cell lysates, and DAXX and FADD
were not assayed. Multiple regression using the least squares
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method was used to identify significant predictor variables,
based on selected response variables. Coexpressed genes were
identified using Pearson’s correlation coefficient. Gene pairs
whose mRNAs correlated across a cohort of samples were
considered to be coexpressed [39]. Correlation probability
values were adjusted using the Bonferroni adjustment for
multiple tests. Univariate analysis of variance (ANOVA)
and t-tests compared transcript concentrations within and
among histotypes and for cell culture treatments. Scatter
plots were generated to ensure the data sets were not unduly
influenced by outliers (data not shown).
3. Results and Discussion
3.1. Transcript Prevalence in Untreated Primary Sarcomas.
We quantified transcript levels in untreated primary sar-
comas using real-time RT-PCR in order to identify coex-
pression patterns within the Fas death pathway. The mean
RT-PCR cycle number for each of 11 genes when averaged
over all 82 sarcomas ranged from 3.1 for CTGF to 12.6
for EGF, equivalent to approximately a 210 difference in
mRNA content. Theoretically, the amount of DNA (derived
from mRNA) doubles with every cycle of PCR during the
exponential phase; therefore, an 8-fold difference in mRNA
template would be approximately 3 cycles apart. Of the
twelve genes evaluated, only EGF (P = 2.6E − 08; mean
cycle number for 11 histotypes = 12.6; range = 8.0–16.4),
FasL (6.7E − 07; mean = 12.3; range = 9.8–15.1), and CTGF
(2.8E − 03; mean = 3.1; range = 1.6–5.6) demonstrated
significant differences (P ≤ 0.01) in mRNA content among
the 11 sarcoma histotypes evaluated; fibrosarcoma with a
sample size of one was not included within the ANOVA.
In contrast to other tumor types, (e.g., carcinomas [40]),
sarcomas frequently exhibit little or no EGF mRNA and/or
protein, when screened by PCR or immunohistochemistry
[41]. Our 82-sarcoma cohort was no exception. EGF tran-
scripts were detected at low concentrations in 75 of the 82
sarcomas. The highest EGF concentrations (i.e., lowest cycle
numbers) were recorded for hemangiopericytomas (mean
cycle number = 8.0, n = 2) and Ewing’s sarcomas (mean
= 8.8, n = 8), while the lowest levels were in synovial
sarcomas (mean = 16.4, n = 9). Of the seven sarcomas
lacking detectable levels of EGF, only twowere synovials. EGF
cycle numbers for individual tumors ranged from 5.9 to 17.3,
equivalent to a 212 difference in mRNA content among the 82
tumors.
High FasL cycle numbers also reflected very low FasL
mRNA concentrations in all 82 sarcomas. FasL and EGF
concentrations were significantly (P ≤ 0.001, ANOVA) lower
than the transcript levels of the other genes inventoried
in this study. Maximum FasL was detected in malignant
fibrous histiocytomas (mean cycle number = 9.8, n = 5)
and in MPNST (mean = 10.6, n = 9), while the lowest
quantities were in synovial sarcomas (mean = 15.1). In-
ducible or constitutively expressed FasL has been reported for
a variety of tumor types, including sarcomas [42, 43]. FasL
protein presumably functions to enhance tumor survival
via immune privilege, although this function has been
challenged, for example [44]. FasL mRNA and protein have
also been detected in tumor cell lines, although Ryan et
al. [45] cautioned against using FasL mRNA alone as an
indicator of FasL expression. Apparently, cells in culture can
maintain constitutive expression of FasL protein in spite of
extensive variations, or even the lack of FasL mRNA pro-
duction. In our study, FasL transcripts were not detected in
SW1353 cells when cultured in complete medium. However,
FasL became transcriptionally and translationally active in
SW1353 cultures, as it does in other cell types [15], when
the cultures were deprived of serum for extended periods of
time.
CTGF was present in all tumors examined and was
particularly abundant in MPNST (mean cycle number =
1.6, n = 9), leiomyosarcomas (mean = 1.6, n = 7), and
chondrosarcomas (mean = 1.7, n = 5). We expected CTGF
concentrations to be high in chondrosarcomas [46], but in
fact, only one of the seven tumors with the highest levels of
mRNA was a chondrosarcoma, while the others consisted of
(two tumors each) MPNST, leiomyosarcoma, and osteosar-
coma.
The remaining nine genes, all of which generated mean
cycle numbers ranging from 3.9 (TGFβ1) to 7.4 (CASP8 and
CASP10), differed little in mRNA content among histotypes
(P ≥ 0.01). These nine genes also showed very low variance
estimates for mRNA content, ranging from 1.6 for CASP8
to 3.9 for Fas. In comparison, variance values for EGF, FasL,
and, CTGF were 10.0, 7.6, and 6.6, respectively.
Our results verify transcription of all 12 Fas-related genes
in sarcomas and suggest amajority of these genes vary little in
expression level (constitutive expression?) within or among
sarcoma histotypes. Expression of the facultative genes FasL
and EGF, on the other hand, varied significantly within and
among histotypes. EGF was the only gene whose mRNA was
not detected in all 82 tumors.
3.2. Coexpression in Tumors and SW1353 Cells. Gene coex-
pression analysis is based on the premise that genes with sim-
ilar functions have similar expression patterns [47]. Coex-
pression data sets, typically derived from microarray studies,
are used to generate coexpression networks which reflect the
interdependence of molecules, cellular processes, and regu-
latory pathways [48]. This analytical approach has been used
to delineate functional gene sets in rice (Oryza) [49], stress
response [50], and cancer [51] and to identify orthologous
genes among distantly related taxa [52].
Coexpressed tumor genes, defined in this study using
Pearson’s correlation coefficients [39], are identified as bold
correlation coefficients in Table 1. Coexpression analysis of
the 82-tumor cohort indicated strong associations between
Fas and six of the seven recognized participants in the Fas
death pathway (DAXX, SMAD3, SMAD7, CASP8, CASP10,
and CFLAR) [53, 54], as well as associations among those
six genes. Interestingly, neither FasL nor EGF correlated
with Fas, while CTGF and TGFβ1 did. We reported strong
correlations between Fas, TGFβ1, and/or CTGF previously
[37, 38]. Also noteworthy is the fact that DAXX, rather than
FADD correlated with Fas, as well as with SMAD3, both
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Table 1: Coexpression matrix for 12 Fas-related genes assayed by RT-PCR in 82 primary sarcomas. Correlation coefficients in bold are
significant at P ≤ 8.0E − 05 using the Bonferroni adjustment for multiple comparisons.
EGF FADD DAXX TGFβ1 CTGF Fas SMAD3 SMAD7 CASP8 CASP10 CFLAR FasL
EGF 1
FADD −0.03 1
DAXX 0.06 0.57 1
TGFβ1 −0.08 0.27 0.37 1
CTGF 0.11 0.25 0.37 0.62 1
Fas 0.17 0.16 0.44 0.57 0.66 1
SMAD3 0.12 0.20 0.55 0.46 0.41 0.52 1
SMAD7 −0.02 0.12 0.33 0.48 0.50 0.53 0.51 1
CASP8 −0.14 0.31 0.54 0.45 0.30 0.49 0.61 0.54 1
CASP10 0.03 0.35 0.43 0.58 0.48 0.52 0.50 0.49 0.69 1
CFLAR −0.06 0.31 0.49 0.43 0.36 0.43 0.52 0.53 0.80 0.71 1
FasL 0.04 0.03 −0.03 0.09 0.35 0.23 −0.07 −0.02 0.01 0.17 −0.07 1
caspases, and CFLAR. FADD is considered the primary
adaptor molecule in the Fas death pathway [55], while the
implementation of Fas-induced apoptosis via DAXX remains
controversial [56, 57]. Ironically, although DAXX acts as an
intermediary to convey proapoptosis signals from the TGFβ
receptors in AML12 hepatocyte and CH33 immature B-cell
lymphoma [18], DAXX did not correlate with TGFβ1 in our
sarcoma samples. Perhaps a correlation between DAXX and
TGFβ would have been evident had we included one or both
TGFβ receptors rather than TGFβ1.
To determine whether coexpression patterns apparent
in the 82-tumor cohort could be induced in vitro with
rhEGF, we used the SW1353 chondrosarcoma cell line to sup-
port our contention that EGF modulates the Fas pathway.
A colorimetric, cell-based ELISA kit was used to verify
EGFR activation following rhEGF stimulation. SW1353 cells
tested positive for EGFR and cells stimulated with rhEGF
and assayed with an α-phospho-EGFR (activated) antibody
displayed significantly higher (P ≤ 0.05) optical density
readings than untreated (control) cells, thus confirming acti-
vation of the EGFR following rhEGF stimulation.
The microenvironment is certainly an influential factor
on all cellular activity. To assess environmental stress on the
cell, we compared the coexpression profiles of untreated con-
trol cultures in complete medium (n = 23) and serum-free
(SF) conditions (n = 18), plus rhEGF-induced cultures (n =
34) against the gene associations apparent in tumors. The
complete medium control cultures consisted of cells grown
under “maintenance” conditions (i.e., exponential prolifera-
tion). SF control cultures were included for two reasons: (1)
tumors in situ reportedly contain quiescent as well as rapidly
proliferating cell populations and serum deprivation (SF)
in vitro induces cellular quiescence [58]; (2) growth factors
are typically applied in vitro under SF conditions following
a minimum 24 h serum deprivation treatment [59], and
extended serum deprivation (≥17 h) has a significant impact
on gene expression [60]. Treated cultures included both
rhEGF and receptor-inhibited/rhEGF-induced samples and
were incorporated into a single “treated” cohort in order to
include within the analysis a wide variety of potential phys-
iological states, any combination of which might influence
coexpression. The correlation matrices representing nine
genes assayed in the two control cohorts are provided in
Table 2, while Table 3 lists correlation coefficients for those
same nine genes in treated cultures.
The most prominent difference among the in vitro and
tumor correlation matrices involved EGF. EGF lacked cor-
relation in the 82-tumor cohort and in SF control cultures,
but correlated with Fas-related genes in rhEGF-induced
cultures and in the complete medium controls, although
the coexpression patterns differed remarkably between these
two responsive cohorts. In particular, EGF correlated with
TGFβ1, CTGF, Fas, and SMAD3 in the complete medium
cohort (Table 2), but not in the rhEGF-induced cohort
(Table 3), while EGF associated with SMAD7, both caspases
and CFLAR in rhEGF-induced cells, but not in the complete
medium controls. This circumstance might have been in re-
sponse to the composition of the serum supplement, which
presumably included growth factors, or may have been in-
duced by the in vitro treatment and harvest schedule em-
ployed in this study. We cannot explain at this time why EGF
lacked correlation in the tumor cohort and in SF controls
(although see below).
Three coexpression patterns remained consistent in all
four cohort matrices: (1) CASP8 and CASP10 correlated
strongly with each other, and both with CFLAR; (2) Fas
correlated with SMAD3; (3) CTGF and TGFβ1 correlated
with Fas. The associations of these respective genes may be
so tightly intertwined and controlled that the genes remained
refractory to the in vitro modulations utilized in this study.
Surprisingly, TGFβ1 lacked correlation with CTGF and
SMAD3 in the rhEGF-induced matrix, in stark contrast to
their strong correlations in the other three matrices. It is well
established that CTGF is induced by TGFβ in mesenchymal
cells [61] and that SMAD3 is directly responsive to TGFβ
stimulation in a variety of cell types [62], so correlations
among TGFβ1, CTGF, and SMAD3 were expected in all
four matrices. A direct association between EGF and CTGF
was demonstrated by Samarakoon et al. [63] when they in-
hibited the EGFR with AG1478, a receptor tyrosine kinase
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Table 2: Coexpression matrices for nine Fas-related genes assayed by RT-PCR in 23 complete medium control (top panel) and 18 serum-
free (SF) control (bottom panel) SW1353 chondrosarcoma cell cultures. Correlation coefficients in bold are significant at P ≤ 1.1E − 03
(Bonferroni’s adjustment).
EGF TGFβ1 CTGF Fas SMAD3 SMAD7 CASP8 CASP10 CFLAR
EGF 1 0.85 0.73 0.63 0.67 −0.17 0.25 0.19 0.16
TGFβ1 0.26 1 0.91 0.84 0.90 −0.16 0.31 0.18 0.18
CTGF 0.29 0.73 1 0.97 0.95 −0.30 0.10 −0.05 −0.03
Fas 0.36 0.92 0.77 1 0.94 −0.41 −0.07 −0.22 −0.19
SMAD3 0.17 0.84 0.55 0.88 1 −0.20 −0.21 −0.04 −0.01
SMAD7 0.60 0.18 0.35 0.13 −0.07 1 0.60 0.64 0.66
CASP8 0.26 0.03 −0.15 −0.02 0.00 0.51 1 0.95 0.94
CASP10 0.42 0.22 −0.01 0.18 0.10 0.52 0.92 1 0.98
CFLAR 0.21 0.35 0.14 0.23 0.14 0.58 0.86 0.90 1
Table 3: Coexpression matrix for nine Fas-related genes assayed by RT-PCR in 34 SW1353 chondrosarcoma cell cultures treated topically
with rhEGF, alone or following EGF/TGFβ receptor inhibition. Correlation coefficients in bold are significant at P ≤ 1.1E−03 (Bonferroni’s
adjustment).
EGF TGFβ1 CTGF Fas SMAD3 SMAD7 CASP8 CASP10 CFLAR
EGF 1
TGFβ1 0.18 1
CTGF 0.22 0.50 1
Fas 0.28 0.87 0.52 1
SMAD3 0.42 0.47 0.36 0.62 1
SMAD7 0.66 0.23 0.17 0.27 −0.07 1
CASP8 0.76 0.26 0.18 0.38 0.54 0.43 1
CASP10 0.74 0.30 0.13 0.38 0.57 0.34 0.96 1
CFLAR 0.57 0.45 0.12 0.50 0.33 0.56 0.80 0.78 1
inhibitor which preferentially blocks EGFR kinase without
reducing expression of EGFR [64], which blocked CTGF
expression in vascular smooth muscle cells. It is possible that
collation of samples pretreated with TGFβ and EGF receptor
inhibitors within the rhEGF cohort is responsible for the lack
of association between TGFβ1, CTGF, and SMAD3 in the
rhEGF-treated samples.
Lastly, a number of gene associations highlighted in the
tumor matrix were not replicated in vitro. This was particu-
larly true for Fas itself. The lack of correlation between Fas
and genes downstream of Fas in all three in vitro matrices
could also be an artifact of the treatment and harvest sched-
ule used for in vitro experiments.
In additional to the 24 h rhEGF in vitro experiments,
we also screened for coexpression in cell cultures stimulated
for 1 h with 5 ng/mL rhEGF, without receptor inhibition,
to further demonstrate the modulatory influence of EGF
on gene transcription. In these experiments, relevant gene
pairs correlated significantly in rhEGF-stimulated cultures,
but not in untreated control cultures (Table 4). FasL mRNA
was not expressed in treated and control cultures; therefore,
it was not included in this analysis.
EGF induces cell growth, migration, invasiveness, and
survival in tumors and in cultured cells [65, 66]; however,
the mechanisms involved remain unclear. Our coexpression
Table 4: SW1353 chondrosarcoma cell cultures respond to rhEGF
(1 ng/mL for 1 h) stimulation under serum-free culture conditions.
Significant correlations are in bold.
Gene pair Control (n = 10) rhEGF (n = 10)
TGFβ1:Fas 0.63 0.92
TGFβ1:SMAD3 0.67 0.96
CTGF:Fas 0.43 0.91
SMAD3:Fas 0.70 0.85
EGF:SMAD7 0.67 0.96
TGFβ1:CTGF −0.17 0.80
analysis complements suggestions made by others that genes
within the Fas pathway respond to EGF stimulation [67–69].
Our coexpression analysis does not, however, clarify whether
the response is prosurvival or prodeath, nor does it identify
which potential Fas ligands were functional. On the other
hand, the analysis laid the foundation for development of
an EGF/CTGF/Fas model, described below, that suggests a
prosurvival function for EGF in mesenchymal cells.
3.3. Fas Ligand Functionality in Sarcomas and SW1353
Cultures. We recently published evidence supporting a mod-
ulatory influence by EGF on transcription within the Fas
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Table 5: Predictive value of EGF, TGFβ1, CTGF, and FasL for Fas, CASP8, and CASP10mRNA concentrations in sarcomas and in serum-free
(SF) and complete medium (CM) control and rhEGF-treated SW1353 chondrosarcoma cell cultures. Refer to Section 3.3 for separation of
tumors into “top 41” and “bottom 41” tumor subcohorts. Significant probability values are in bold.
Samples Response gene
Predictor genes
EGF TGFβ1 FasL CTGF
82 tumors Fas 0.11 0.09 5.0E− 03 1.8E− 04
Top 41 tumors Fas 2.0E−03 0.48 9.0E− 04 0.01
Bottom 41 tumors Fas 0.75 0.26 0.15 4.0E− 04
82 tumors CASP8 0.21 0.03 0.06 0.94
Top 41 tumors CASP8 0.34 3.5E− 03 9.3E− 03 0.96
Bottom 41 tumors CASP8 0.13 0.89 0.35 0.50
82 tumors CASP10 0.70 0.01 1.4E− 04 0.38
Top 41 tumors CASP10 0.36 2.9E− 03 0.04 0.92
Bottom 41 tumors CASP10 0.62 0.88 5.9E− 03 0.11
SW1353 SF control Fas 0.31 7.4E− 05 n/a 0.22
SW1353 CM control Fas 0.41 0.57 n/a 9.5E− 06
SW1353 rhEGF Fas 0.24 6.8E− 09 n/a 0.33
SW1353 SF control CASP8 0.23 0.47 n/a 0.25
SW1353 SF control CASP10 0.09 0.20 n/a 0.19
SW1353 CM control CASP8 0.50 2.9E− 03 n/a 2.8E− 03
SW1353 CM control CASP10 0.80 1.1E− 03 n/a 3.6E− 04
SW1353 rhEGF CASP8 6.3E− 07 0.28 n/a 0.70
SW1353 rhEGF CASP10 1.0E− 06 0.09 n/a 0.29
apoptotic pathway in sarcomas [38]. Ten Fas-related genes
were assayed by real-time RT-PCR in a cohort of 57 primary
sarcomas. The 57 sarcomas were arbitrarily sorted into two
subcohorts based on tumor EGF mRNA content. Multiple
regression analysis employing FasL and TGFβ1 as predictor
variables, and Fas as the response variable, indicated that
TGFβ1 expression predicted Fas mRNA concentrations in
the low-EGF subcohort, while FasL predicted Fas content in
the high-EGF subcohort. We concluded that Fas ligand func-
tionality correlated with, andmay bemodulated in, sarcomas
by EGF.
In our current analysis involving 82 primary sarcomas,
57 of which were used in the original analysis [38], we in-
cluded EGF and CTGF as predictor variables within the
Fas/FasL/TGFβ1 multiple regression model. Inclusion of
CTGF was based on evidence published previously by this
lab that showed a very strong correlation between CTGF and
FasmRNA content in sarcomas with low-EGF content, which
lacked correlation in sarcomas with higher-EGF content
[37]. When the relationships between Fas and the four pre-
dictor variables were analyzed over the 82-tumor cohort,
CTGF and FasL predicted Fas mRNA content, while TGFβ1
and EGF lacked predictive value (Table 5). Removal of EGF
and CTGF from the regression model showed FasL and
TGFβ1 predicted Fas for the 82-tumor cohort equally well
(data not shown). Division of the 82 tumors into two EGF-
related subcohorts of 41 tumors each, and with EGF and
CTGF removed from the regression, produced results con-
sistent with our previous findings [38]. These results imply
the association between Fas and TGFβ1 may be coordinated
through CTGF. Surprisingly, EGF, which lacked predictive
value for the 82-tumor cohort and was not included as a
predictor variable in [38], became a significant predictor of
Fas when the 82 tumors were arbitrarily divided into the two
EGF-related subcohorts and CTGF was included within the
analysis (Table 5).
CASP8 and CASP10 function downstream of Fas, and
activation of CASP8 (and probably CASP10) via the Fas
death-inducing signaling complex is a requirement for Fas-
induced cell death. We questioned whether the associations
involving Fas and its potential ligands described above would
carry over to downstream genes. Of the four predictor genes
evaluated, TGFβ1 predicted CASP8 and CASP10 content
in the 82-tumor cohort, but only marginally, while FasL
effectively predicted CASP10 but was marginal for CASP8
(Table 5). Neither CTGF nor EGF successfully predicted
caspase content. With division of the tumor cohort into the
two EGF-related subcohorts, we expected FasL to dominate
in the high-EGF subcohort and CTGF to provide predictive
power in the low-EGF subcohort. Our regression model
suggested FasL and/or TGFβ1 could both be functional in
the high-EGF subcohort (P ≤ 0.01), but FasL, rather than
CTFG or TGFβ1, was significant for the low-EGF cohort, and
then only for CASP10 (P = 5.9E−03). Our interpretation of
these results is that EGF and CTGF are “prosurvival” genes
and, therefore, may correlate with, but do not necessarily
induce, these two caspases. FasL and TGFβ1, on the other
hand, activate prodeath CASP8 and CASP10 via Fas.
To evaluate these same gene associations in cultured
cells, SW1353 cultures were stimulated with rhEGF for
24 h and harvested for RT-PCR. The predictive values of
EGF, TGFβ1, and CTGF for Fas and both caspases are
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also provided in Table 5. FasL was not included in this
analysis. TGFβ1 was the only significant predictor of Fas in
SF controls and rhEGF-treated cultures, while CTGF filled
that role for cultures maintained in complete medium. Both
TGFβ1 and CTGF retained predictive value for caspases in
complete medium control cultures, but neither TGFβ1 nor
CTGF showed predictive value for caspases in SF controls or
in rhEGF-treated cultures. Collectively, trends in the in vitro
data support our tumor analysis. However, the lack of FasL
expression by control and treated cell cultures undoubtedly
affected the molecular coordination of the three other genes
included as predictor variables within the regression model.
This in turn made it difficult to clearly discern patterns that
were statistically attributed to EGF activity in the sarcomas.
In addition, the range of EGF mRNA concentrations within
the in vitro cohorts varied little between and among samples.
The lack of variation in EGF expression made it impossible
to explore the impact of EGF content on expression patterns.
In view of the tumor and in vitro results described above,
we propose that three genes—FasL, TGFβ1, and CTGF—
are intimately involved in the regulation of the Fas death
pathway, and their coordination and respective contributions
are modulated by EGF in sarcomas. Therefore, based on our
collective findings, we suggest a novel role for EGF as a co-
regulator of the Fas pathway in mesenchymal neoplasms.
3.4. Derivation of the EGF/CTGF/Fas mRNA Model. Growth
factors are mitogens [70]. Apoptosis, on the other hand, is
programmed cell death. Given the opposing functional roles
of proliferation and apoptosis, these two processes must be
coordinated. We propose that EGF contributes to that co-
ordination in sarcomas by regulating the expression and/or
functionality of the proapoptotic and/or anti-apoptotic pro-
teins: FasL, TGFβ1, and CTGF. The possibility of “crosstalk”
among EGF/TGFβ1/CTGF/FasL and interactions between
EGF/TGFβ receptor signaling and the Fas death pathway
have been reported previously [34]. To develop our EGF/
CTGF/Fas model, we ranked the 82-sarcoma cohort by de-
scending EGF mRNA content. We then used a series of
partially overlapping, 15-tumor, multiple regressions that
collectively incorporated all 82 tumors in order to identify
which predictor variable(s)—FasL, TGFβ1, and CTGF—best
described Fas content within each 15-tumor cohort. The first
regression encompassed tumors number 1 through number
15, the second regression incorporated tumors number 2
through number 16, and so forth. The final regression an-
alyzed 15 tumors containing little or no EGF mRNA. The
resulting probability “indices” for the three potential Fas lig-
ands are illustrated in Figure 1. For this analysis, we view the
resulting probabilities as indices, rather than as probability
values per se, due to the statistical requirements associated
with the testing of overlapping samples [71].
Our mRNA model formulates testable predictions re-
garding Fas ligand functionality in relation to tumor EGF
content. The model suggests FasL may be the primary, if not
the only, functional Fas ligand in mesenchymal tumors sup-
porting high concentrations of EGF mRNA, since it was the
only ligand of the three with indices ≤0.05 for the sarcomas
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Figure 1: Probability indices for predictor variables FasL, TGFβ1,
and CTGF regressed against Fas in 82 primary sarcomas.
within this EGF range. As the EGF mRNA content of tumors
decreases, FasL is replaced by CTGF as the “best predictor,”
which is replaced in turn by TGFβ1. There appears to be
a second abbreviated tumor zone represented by tumors
number 41 through number 56 where FasL again predicts Fas
content. This zone is overlapped and extended substantially
by a second CTGF zone (tumors number 44 through number
73). The Fas concentrations in tumors number 74 through
number 82, which contained little or no EGF mRNA, could
not be predicted by the three potential ligands. The tran-
sition from one potential ligand to the next is gradual and
overlapping.
The presumed interrelationships among EGF, Fas, and
the three potential Fas ligands are depicted in our EGF/
CTGF/Fas model (Figure 2). We have included within this
schematic tumors that contained FasL, EGF, and TGFβ1
proteins, as defined by ELISA. In the schematic, all three
circles represent the same tumor continuum, starting with
tumor number 1 which had the highest concentration of EGF
mRNA and ending with tumor number 82, which lacked
EGFmRNA. The hash marks through the outer circle delimit
the presumed functional distribution of each potential Fas
ligand (i.e., range of successive tumors for which the index
for that variable was≤0.05, as shown in Figure 1). For exam-
ple, FasL predicted Fas mRNA content in tumors number 1
through number 24, CTGF in tumors number 11 through
number 34, and so forth. The middle circle identifies the
tumors containing FasL (tumors number 1 through number
11) or EGF (number 13 through number 30) protein. The
hash marks through the small, inner circle represent the 11
tumors that contained TGFβ1 protein. We derive three pre-
dictions from the mRNA model: (1) FasL protein induces
EGF transcription; (2) EGF subsequently modulates TGFβ1
and CTGF expression and activity; (3) CTGF defines TGFβ1
activity, which ultimately favors cell survival over cell death.
EGF promotes cell survival, and it is our hypothesis that
EGF signaling is one mechanism used by sarcomas to negate
FasL-induced apoptosis. A particularly relevant finding re-
garding this topic was reported by Reinehr et al. [72]. They
found for quiescent hepatic stellate cells (HSCs), which
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Figure 2: EGF/CTGF/Fas mRNA model.
are typically resistant to FasL-induced apoptosis, that FasL,
generally considered to be a prodeath molecule, stimulated
EGFR signaling, which in turn enhanced HSC survival. In
other words, in quiescent HSCs, FasL and other death re-
ceptor ligands function as mitogens. The process is EGF de-
pendent and involves a protease-mediated liberation of EGF,
which subsequently activates the EGFR. Activation of the
EGFR in quiescent HSC involves phosphorylation of the
EGFR tyrosine residues 845, 1173, and 1045. Phosphory-
lation of tyrosine 1045 mediates EGFR internalization. In
hepatocytes, FasL also activates the EGFR, but the process
is not ligand dependent, nor is the EGFR internalized. The
proposed pathway in hepatocytes involves FasL activation
of p47phlox, a regulatory subunit of NADPH oxidase. The
resulting oxidative stress induces the Src family kinase Yes,
which in turn induces EGFR phosphorylation at Tyr845 and
Tyr1173. Tyr1045 is not phosphorylated, hence no EGFR inter-
nalization. The reactive oxygen species (ROS) signal activates
JNK, which is a requirement for Fas-related apoptosis
[73]. The JNK pathway is not activated in FasL-stimulated
quiescent HSC.
The mRNA samples used in our tumor analysis were
derived from untreated sarcomas which presumably con-
tained both quiescent and proliferating cell populations.
Solid tumors frequently contain a significant proportion of
quiescent cells. The sarcoma mRNA indices, which defined
our model, may typify the quiescent populations within
those tumors. Since the tumors were not exposed to radiation
or chemotherapy prior to resection, each sample should have
typified a tumor that was undergoing routine tumor mainte-
nance (progression/stasis) at the time of resection. Accord-
ingly, the presumptions guiding the formulation of our
mRNA model include the following: (1) the mRNA prob-
ability indices generated by the multiple regression analysis
reflect the functional distributions of the respective genes,
alone or in combination with other genes; (2) the 82 sarco-
mas used to develop the model had all been exposed to FasL
protein within a presently undefined time frame; (3) by rank-
ing the tumors according to descending EGFmRNA content,
we mapped incremental “steps” in the physiological response
of tumors to FasL exposure; (4) the three potential Fas lig-
ands are modulated by EGF; (5) for this particular apoptotic
pathway, EGF defines whether a cell lives or dies by regulating
TGFβ1 and/or CTGF; (6) the EGF-induced response to FasL
is universal amongmesenchymal cells (i.e., transcends tumor
cell-of-origin and benign versus malignant).
We believe this approach allows us not only to evalu-
ate the interrelationships between response and predictor
variables within each 15-tumor cohort, but also to visualize
progressive changes in the respective contributions of predic-
tor variables attributable to incremental reductions in EGF
mRNA. Fundamental to this approach is the assumption that
transcription reflects the physiological state of the untreated
tumors at the time of resection and is not contingent upon,
nor specific to, tumor histotype or cell of origin. Transcript
modulation by microRNAs may be partially responsible for
this. We consider our ranking of tumors by descending EGF
mRNA content in order to evaluate collectively the influence
of EGF on gene transcription within the Fas death pathway
as analogous to viewing successive frames of a 35mm movie.
Each tumor (frame) provides a time-specific “snapshot”
of the physiological state of that tumor (content of the
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Figure 3: Distribution of EGF protein in 21 sarcomas included
within the 82-sarcoma cohort.
movie), but by itself may not provide sufficient information
to discern a sarcoma-wide transcriptional response (theme
of the movie). It is only when all of the tumors (frames)
representing multiple histotypes are combined into a single
cohort, ranked by decreasing EGF content, and then viewed
in its entirety (i.e., in context) that the transcriptional
response (theme) becomes apparent.
3.5. Tumor EGF and FasL Protein Expression Conform to
the mRNA Model. Our model is based on tumor mRNA
content. Arguably, the ligand functionality indices illustrated
in Figure 1 could represent one of an infinite number of
possible patterns generated through the randomization of
the 82 sarcomas. However, we believe our model makes
testable predictions regarding protein expression, and their
confirmation will strengthen our hypothesis. We propose
that sarcomas with the highest EGF mRNA concentrations
represent tumors stimulated to undergo EGF transcription.
Transcription is repressed subsequently and ultimately ter-
minated when adequate EGF protein becomes available to
carry out the prescribed function(s) or the EGF-mediated
response is no longer necessary. If our mRNA model is
correct, EGF protein should be present in sarcomas with
high(er) levels of EGF mRNA, but not necessarily in tumors
with the highest concentrations of EGF mRNA, and reduced
in content or lacking in sarcomas with little or no EGF
mRNA. To test this prediction, we quantified by ELISA the
EGF protein content in 21 of the 82 sarcomas used for this
proposal. The 21 tumors represented the only sarcomas in
the 82-tumor cohort whose soluble proteins were available
for use. The EGF mRNA concentrations of the 21 tumors
spanned the entire range of EGF concentrations represented
within the 82-tumor cohort. A majority of the sarcomas with
detectable levels of EGF protein contained high concentra-
tions of EGF mRNA (Figure 3). The primary EGF-protein-
containing tumors are labeled number 13 through number
30 in Figure 3. Six of the 21 sarcomas lacked detectable levels
of EGF protein; all six had EGF mRNA concentrations below
the level of tumor number 30. The EGF protein pattern
conforms to our model.
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Figure 4: Distribution of FasL protein in 21 sarcomas within the
82-sarcoma cohort.
We then quantified FasL protein concentrations in the
same 21 sarcoma samples. FasL mRNA was detected in all
82 sarcomas, at concentrations equivalent to EGF mRNA
content. Our mRNA model predicts that FasL is functional
in high-EGF tumors, but may also show limited activity in
the mid-EGF range. Initially, we assumed FasL protein would
predominate in tumors that also contained high concentra-
tions of FasL mRNA, in a manner analogous to EGF. This
proved not to be the case. When the 82 sarcomas were ranked
by decreasing FasL mRNA concentration, rather than by
decreasing EGF, the five FasL-protein-bearing tumors were
distributed across the entire 82-tumor cohort (represented
by tumors number 9, number 25, number 57, number 58,
and number 79). On the other hand, when the 82 tumors
were ranked by decreasing EGF mRNA content (Figure 4),
FasL protein was detected only in tumors with high EGF
mRNA concentrations. This protein pattern conforms to
our mRNA model since the distribution of FasL-protein-
bearing sarcomas along the 82-tumor EGF mRNA gradient
overlaps the tumor zone where FasL is the only significant
predictor of Fas mRNA content (refer to Figure 1). The
protein analysis highlights four important points regarding
FasL in mesenchymal tumors: (1) EGF and FasL mRNA
concentrations did not correlate in the 82 primary sarcomas;
therefore, why is FasL protein present only in sarcomas
containing the highest concentrations of EGF mRNA? Might
FasL protein induce EGF expression in mesenchymal tissues,
as was the case for a variety of EGFR ligands induced by FasL
in human epidermis [74]? (2) Why was there no discernable
association between FasL mRNA concentration and the
presence of FasL protein? A lack of correlation between
FasL mRNA and protein expression was also reported by
Ryan et al. [45]. (3) Is the stability of the FasL protein
influenced by EGF protein (i.e., FasL-protein-bearing tumors
were “upstream” of a majority of the tumors containing
EGF protein)? (4) Does the lack of EGF protein render cells
functionally receptive to FasL transcription and translation?
Since stimulation of human epidermal carcinoma A431 cells
with EGF induces FasL expression [75], we suggest EGF may
also impact FasL in mesenchymal cells.
Sarcoma 11
0
100
200
300
400
500
600
700
800
2 8 13 16 27 29 41 55 63 80 82
Tumor (decreasing EGF mRNA content)
p
g
T
G
Fβ
1/
m
g
to
ta
lp
ro
te
in
TGFβ1
Figure 5: Distribution of TGFβ1 protein in 21 sarcomas within the
82-sarcoma cohort. The line labeled TGFbeta1 overlays the tumors
within which TGFβ1 significantly predicted Fas mRNA content.
3.6. TGFβ1 Protein Expression Deviates from the mRNA
Model, While CTGF Conforms to the Model. We propose that
TGFβ1 and CTGF are principal participants within the Fas
death pathway, and their respective contributions and poten-
tial cross-interactions within the pathway are modulated by
EGF. TGFβ1 mRNA significantly predicts Fas mRNA content
in tumors number 23 through number 40, while CTGF dom-
inates in tumors number 11 through number 34, and again in
tumors number 44 through number 73 (Figure 1). We used a
commercially available ELISA kit to quantify TGFβ1 protein
concentrations in the 21 sarcoma samples described above,
but used a dot blot assay to document the presence or lack of
CTGF protein in the samples, since commercial ELISA kits
for CTGF are currently unavailable. Eleven of the 21 tumor
samples assayed by ELISA contain TGFβ1 protein (Figure 5),
and seven of the 11 (64%) tumors are positioned down-
stream of tumor number 23. However, eight of the 21 assayed
sarcomas are positioned upstream of tumor number 23, and
four of the eight also contained TGFβ1 protein. We found
(1) the presence of TGFβ1 protein within a tumor sample
lacked any discernable association with that tumor TGFβ1
transcript concentration and (2) TGFβ1-bearing tumors did
not cluster along the EGF-derived tumor continuum. These
results suggest that TGFβ1 translation or protein stability in
sarcomas is probably not influenced directly by EGF, even
though TGFβ1 contribution to the Fas pathway may be
influenced directly or indirectly by EGF.
A dot blot analysis documented the presence of CTGF
protein in 10 of the 21 sarcoma samples (Figure 6). We
blotted undiluted total soluble proteins from each of the 21
sarcoma samples and probed the dots with an anti-CTGF
antibody. To normalize the data relative to each sample total
soluble protein, each dot was scored numerically based on a
visual estimate of dot intensity. The resulting numeric scores
were divided by the known concentration of total protein
within each sample. This procedure generated a “CTGF
index.” The ordinate in Figure 6 represents the CTGF index,
while tumor (ranked by descending EGF mRNA content) is
represented on the abscissa. We also included within Figure 6
0
1
2
3
4
5
6
1 9 17 25 33 41 49 57 65 73 81
Tumor (descending EGF mRNA content)
C
T
G
F
n
de
x
CTGF predicts Fas CTGF predi
i
cts Fas
Figure 6: Sarcoma samples containing CTGF protein based on a
dot blot analysis. The lines labeled “CTGF predicts Fas” overlay
the tumors within which CTGF significantly predicted Fas mRNA
content. Refer to Results and Discussion for derivation of CTGF
Index.
the range of tumors whose CTGF mRNA content predicted
Fas transcript content (shown as a dark line in Figure 6).
CTGF protein predominated in the tumors whose CTGF
mRNA content served as the best predictor of Fas mRNA
content. Thus, the dot blot results lend additional credence
to our premise that CTGF associates with Fas.
3.7. Mechanism of Action. Our preliminary data and recent
publications support our hypothesis that viable sarcoma
cells regulate the Fas death pathway by activating EGF,
which in turn influences the activities of TGFβ1 and CTGF.
Precedence for this hypothesis was provided by Reinehr et
al. in 2008 [72]. We suggest inhibition of the Fas death
pathway by CTGF in mesenchymal cells may occur directly
(i.e., by binding to and thereby blocking the activities of
key proteins), or indirectly, through CTGF association with
EGF- or Fas-related pathways. CTGF, like other members of
the CCN family, is composed of four conserved sequence
motifs that are considered to be highly interactive with
other biomolecules [76]. Although a number of proteins
reportedly bind to CTGF [77, 78], with the exception of
TGFβ1, none of the binding partners reported to date are
recognized components of the Fas death pathway. Therefore,
it is unlikely that the inhibitory activities of CTGF result
directly from physical contact with Fas-related proteins, or
even through competition with relevant proteins.
Although we can only speculate at this time, a likely
scenario involves the association of CTGFwith Fas- or EGFR-
associated pathways. A candidate EGFR pathway involves c-
Jun NH2-terminal kinase (JNK). Chen et al. [79] reported
recently that cancer cells in general depend on constitutive
activity of Fas, stimulated by FasL, for optimal growth and
that the tumorigenic activity of Fas is mediated by a JNK.
JNK is known to induce CTGF expression, typically via
TGFβ, in a variety of cell systems [80, 81]. CTGF subsequent-
ly activates MAPK/ERK [82–84], and activated MAPK/ERK
blocks Fas-induced apoptosis [85]. Unfortunately the mech-
anism(s) involved in the MAPK inhibition of Fas-induced
apoptosis are unknown [86]. Therefore, based on the
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literature, we propose that proteins involved with the ECM
[87] may function in concert with CTGF and MAPK/ERK
to block Fas-induced apoptosis; CTGF binds to integrin
αvβ3 [88] and, when coupled with activated MAPK/ERK,
ultimately promotes cell survival [89].
The study has substantial limitations. Tissue culture and
in vitro data is anything but conclusive in terms of its rel-
evance to the clinical situation, yet we hope this work will
spur other efforts to look into this highly relevant pathogenic
pathway with more robust modeling. This cohort represents
a heterogenous group of rare tumors which generates a great
detail of data noise and variability which can corrupt our
analysis. However, the common theme across the cohort is
that they are mesenchymal-derived neoplasms. In terms of
microenvironment effect, gene expression profiles are cer-
tainly highly, and perhaps too, sensitive. As Heisenberg pos-
tulated in 1927, it is almost impossible to measure anything
without affecting it.
4. Conclusion
To the best of our knowledge, this is the first data set in sar-
comas detailing a potential growth factor/mitiogenic effect
on FasL-mediated apoptosis. Although historically EGF has
not been associated with cells of mesenchymal origin, we
have documented in previous studies and in the current
analysis an apparent direct relationship between EGF and the
transcription of selected Fas-associated genes. We suggest the
activities of other growth factors, such as TGFβ1 and CTGF,
may be regulated (or at least initiated) by EGF in mesenchy-
mal cells. Our tumor and in vitro data strongly support a
role for EGF modulation of Fas-induced cell death, probably
through activation of CTGF. Mechanistically, CTGF may be
induced by EGF in response to FasL stimulation. CTGF
in turn activates a relevant pathway(s) (i.e., MAPK/ERK),
and the activated pathway(s) blocks Fas-induced apoptosis.
Further proteomic and in vivo studies will be necessary to
substantiate this theory. However the basic tenet, derived
from a consensus within the literature, is that CTGF is
principally a prosurvival protein. This scenario therefore
represents a novel role for EGF and CTGF as regulators of
Fas-induced cell death in mesenchymal neoplasms.
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